Purpose This study was undertaken to identify and compare the prognostic value of gene expression, chromosomal, and clinico-pathological data for the prediction of subsequent metastases in patients with primary uveal melanoma. Patients and Methods For comparison of different sets of predictor variables diagonal linear discriminant analysis was used. Chromosomal events were assessed by comparative genomic hybridization and gene expression profiling by microarray. Twenty-eight patients with a median follow-up of 68 months were analyzed, of whom 12 had developed subsequent metastases. Results Diagonal linear discriminant analysis with crossvalidation of gene expression data detected 42 genes as differentially expressed in metastasizing vs non-metastasizing uveal melanomas in all 28 cases. Comparing quantitative scores of discriminant analysis, grouping precision was significant better with gene expression profiling compared to comparative genomic hybridization (P ¼ 0.01) and to clinical data (P ¼ 0.001). Two published gene lists associated with monosomy 3 and metastatic tumor growth were used as classifier for discriminant analysis and yielded superior classification in patients with and without subsequent metastases than chromosomal or clinico-pathological data. Conclusion In our patient cohort gene expression profiling of primary uveal melanoma tissue was superior to clinicalpathological and chromosomal analysis to assess for the risk of subsequent metastases.
Introduction
Uveal melanoma can be locally treated using a variety of methods, but there is no indication that any of these modalities will influence the risk for development of hematogenous spread, usually to the liver, 1 which in almost all patients will be fatal within months 2, 3 to years. 4 Thus, there are two basic groups of patients according to clinical course, namely patients in whom the tumor will remain confined to the eye, and a second group of patients who will develop hematogenous metastases during follow up. Owing to the absence of lymphatic drainage of the uvea, there is no relevant third group of patients with lymphatic spread. This two-group model should allow comparison of different risk factors from different data sources in relatively small patient cohorts.
A number of clinical and histological risk factors have been defined over the last 3 decades, among these are the clinico-pathological factors like location, extraocular growth, ciliary body (CB) involvement and the epitheloid-cell tumor type. [5] [6] [7] [8] [9] Presence of tyrosinase transcripts in peripheral blood, suggesting circulating melanoma cells, has also been linked to subsequent appearance of metastases. 10, 11 Almost 10 years ago, monosomy 3 was defined as a strong chromosomal risk factor, 12 which appeared to be superior to all clinical and histological factors in the prediction of subsequent metastasis. Subsequently, gene expression profiling has defined gene expression patterns that are associated with monosomy 3 13 and recently, gene expression patterns, which are associated with the development of metastases independent of clinical risk factors. 14 We here report on a comprehensive approach comparing gene expression profiling and comparative genomic hybridization (CGH) with clinical and histological data for all analyzed patients. The analysis was performed in a group of 28 patients with primary uveal melanoma with a follow-up ranging from 3 to 7 years, who had received enucleation or tumor excision as primary treatment for large uveal melanoma. The comprehensive approach with discriminant analysis of the same type for clinico-pathological, chromosomal and gene expression data offers the possibility to compare the value of each data set for the classification of patients into groups according to their risk for the development of subsequent metastases. The clinico-pathological data was separately analyzed for the prediction of metastases-free survival. In addition, the value for risk assessment of subsequent metastasis of published gene expression data associated with monosomy 3 13 and predicting metastatic phenotype, 14 respectively, was verified.
Materials and methods

Patients and tumor samples
Patients with uveal melanoma from our hospital were included into this study, if shock-frozen tissue was available from enucleation or tumor excision as primary therapy, and if the follow-up period since primary surgery exceeded 3 years. The investigation was approved by the institutional ethic committee. The clinical characteristics of the primary uveal melanoma considered included tumor localization, CB involvement, extraocular tumor growth, largest tumor diameter, tumor height, and dominant cell type. The patient's charts were reviewed and the patient's ophthalmologist and/or general physicians were contacted to verify follow-up information. Chromosomal data were coded as þ 1 (intensity 41.17), 0 (intensity between 0.85 and 1.17) and À1 (intensity o0.85). Gender was coded as 1/2 (female/ male), metastases, ciliary body involvement (CB), and extraocular tumor growth EOE as 0/1 (no/yes), tumor type 1/2/3 (epitheloid, mixed, spindle), largest tumor diameter (LTD), tumor height, and age at diagnosis were coded as quantitative variables.
Comparative genomic hybridization
The results include:
(1) Descriptive analyses. Patient cohorts, clinical and pathological data, and chromosomal events. (2) Primary analysis (comparative supervised learning).
The primary aim of the statistical analysis was the comparison between the three subsets of potential predictors (gene expression data, chromosome data, clinicopathological data) with regard to their prognostic value. To this aim, the robust method of diagonal linear discriminant analysis 16 with crossvalidation was applied to each of the three subsets separately. To avoid bias, crossvalidated classifiers were constructed using the 'leaving one out'-method. 16 Classifiers were standardized so that positive values corresponded to a correct classification for patients, both with and without metastases. The size of the values further quantified the confidence of this classification. Finally, the classifiers were compared between the three sets of prognostic variables using the Wilcoxon test for paired samples. One set of prognostic variables was considered superior to another one if the values of this classifier were significantly larger than those of the other one. Additionally, the following secondary analyses were performed: (3) Unsupervised learning for all probe sets: Cluster analysis with squared euclidean distance and average linkage aggregation was applied for all probesets not classified as irrelevant according to their p-detection value against background. (4) Classifying genes: Additionally, based on preselected probe sets in each crossvalidation step of the gene expression data the set S i was determined, which contained 100 probes with the highest absolute standardized difference among all 8465 preselected probe sets. Fifty probes were present in all 28 sets S i and titled as classifying genes. For descriptive purpose only, a second cluster analysis was performed with the 50 classifying probe sets. (Genespring software: hierarchical cluster analysis, standard correlation). As it was not the primary aim of our analysis to identify classifying genes, genes were not selected according to a prespecified value of the Force Detection Rate (FDR 
Results
Patient cohort
Out of 32 patients identified to fulfill entry criteria for the analysis, 28 patients could be included into the study.
Reasons for non-inclusion were insufficient DNA (n ¼ 2) or RNA (n ¼ 2) quality. All 28 patients had received enucleation or tumor excision as primary treatment and 12 patients had developed subsequent metastases. The median follow-up since primary treatment was 68 months, ranging from 37 months to 91 months. The patient characteristics are shown in Table 1 .
Clinical and pathological data
The entire patient cohort had large tumors requiring enucleation or excision. The clinico-pathological data listed in Table 1 were analyzed by univariate KaplanMeier survival analysis. Metastases-free survival was 
Chromosomal events
Chromosomal gains and losses are summarized in Figure 1 . The most frequent events involved chromosomes 3, 6, 8, and Y. A complete loss of one chromosome 3 was found in 11 of 28 cases including nine of 12 cases with subsequent metastases, supporting the major role of monosomy 3 for metastatic phenotype. Interestingly, one sample (047-00) from a patient with metastases revealed trisomy 3. Two samples from patients with metastases (226-97, 193-97) displayed no aberration of chromosome 3. The gene expression pattern of samples 047-00 and 226-97 were grouped by discriminant analysis (see below) to patients with metastases whereas sample 193-97 was classified to patients without metastases. In the samples from two patients without subsequent metastases (210-97 and 108-97) monosomy 3 was detectable. The first of these samples was classified to the group with subsequent metastases, whereas the second was classified to the group without subsequent metastases. Variable partial chromosomal gains in the short arm of chromosome 6 and one complete trisomy of chromosome 6 were exclusively detected in the group of patients without subsequent metastases (nine of 16 patients without subsequent metastases). Among these was one patient (108-97) with a 6p gain coinciding with monosomy 3 and no metastases. Complete trisomy 8 was detected in three patients without metastases, including two patients with monosomy 3 without metastasis, whereas loss of the short arm of chromosome 8 occurred in five patients with monosomy 3 and metastatic disease. This finding indicates in our study that chromosomal gains in chromosome 6p and 8p are associated with a better outcome of the patients.
Data analysis
Preselection of genes
On the basis of the distribution of p-detection values a total of 8465 probe sets were preselected with a p-detection value (against background) of below 0.02 in at least 13 samples.
Primary analysis (supervised learning): comparison of gene expression data and chromosomal events to clinico-pathological data as prognostic factors
Comparison of the grouping precision by diagonal linear discriminant analysis with crossvalidation yielded a significant ranking between gene expression, chromosomal, and clinicopathological data in classifying patients corresponding to development of metastases. Discriminant analysis applied to gene expression data grouped 26 of 28 patients correctly (Figure 2c) . The same type of analysis applied to CGH data grouped 23 of 28 samples correctly, and when applied to the clinico-pathological data, 16 patients were grouped correctly (Figure 2a and b) . Considering the quantitative discriminant scores, the grouping precision of the gene expression analysis was significantly superior to chromosomal data (Po0.01) and to clinico-pathological factors (Po0.001, Figure 2d ).
Secondary analysis (unsupervised learning)
The unsupervised analysis based on 8465 probe sets yielded a classification into two groups (groups A and B), with 12 of 11 patients with subsequent development of metastases clustering in group A, and 14 of 15 patients without metastases clustering in group B. Sample 210-97, which is one of the two samples without subsequent development of metastases and monsomy 3, was separately grouped (Figure 3 ).
Secondary analysis (gene selection)
To identify the most prominent classifying genes, that is the genes differentially expressed in all samples of metastasizing vs non-metastasizing tumors, the 100 probe sets with the highest absolute standardized difference among all 8465 preselected probe sets were considered. Of these, 50 probe sets were detected as classifiers on the basis that they appeared in every step of the 'leaving one out'-method crossvalidation analysis. These defined 50 probe sets were annotated and 42 genes were identified. To visualize the gene expression pattern of the 50 classifying probe sets a hierarchical cluster analysis was performed and yielded a classification into two groups (Figure 4 ).
Secondary analysis (application of published gene lists as classifier)
To analyze the classification accuracy of the published gene lists by Tschtenscher 13 and Onken 14 in our own data set, gene lists were transformed to coding of HG-133A Affymetrix GeneChip and further used as classifier for diagonal discriminant analysis. On the level of probe set identifiers an overlap of five discriminant genes was found compared to a gene list associated with monosomy 3 13 and an overlap of four discriminant genes compared metastases n n n n n n n n n n n n n n n n y y y y y y y y y y y y 108-97  026-97  210-97  219-97  013-99  274-97  174-96  187-96  179-96  097-98  135-98  150-99  001-98  051-98  139-97  101-99  154-99  147-99  005-97  127-99  226-97  047-00  130-96  075-99  071-00  098-99  178-97  193-97   Chromosome   1p  1p   1q  1q  2p  2p  2q  2q  3p  3p  3q  3q  4p  4p  4q  4q  5p  5p  5q  5q  6p  6p  6q  6q  7p  7p  7q  7q  8p  8p  8q  8q  9p  9p  9q  9q  10p  10q  11p  11q  12p  12q  13q  14q  15q  16p  16q  17p  17q  18p  18q  19p  19q  20p  20q  21q  22q  Xp  Xq  Y   10p  10q  11p  11q  12p  12q  13q  14q  15q  16p  16q  17p  17q  18p  18q  19p  19q  20p  20q  21q to the gene list associated with metastatic phenotype. 14 Both gene lists were able to group our patients as high-risk or low-risk patients for subsequent metastases just as for our gene expression data. Both gene lists grouped 25 of 28 samples correctly (data not shown).
Discussion
The primary objective of our study was to investigate the precision of gene expression profiling in comparison to clinico-pathological and chromosomal data of uveal melanoma to assess the risk of development of subsequent metastases. Results of discriminant analyses were standardized to compare different sets of predictor variables, namely gene expression, CGH and clinico-pathological data. In our series the primary uveal melanoma lesions were all large tumors, which are typically treated by enucleation or excision and thus yield adequate tissue for analysis. Assuming that enucleation and excision had no influence of the metastatic spread, both treatment groups were analyzed together. The analysis of the metastasesfree survival and the discriminant analyses based on clinico-pathological data demonstrated only a poor (!) and N ij (~) as described in the Methods, the circles (K) refer to the value of the classifier for the sample left out in the respective step. The zero line marks the cutoff between classification into metastases (upper half) and no metastases (lower half). In the displays correct/false classification and the distance to the cutoffs can be compared between different samples and different sets of prognostic variables. Samples were grouped into metastasizing and non-metastasizing uveal melanoma discriminated by negative and positive classifier value, respectively. From 28 samples 26 were classified according to subsequent developed metastases by gene expression data (c), 23 by chromosomal data (b) and 16 by clinico-pathological data (a). Grouping precision (d) Wilcoxon test for dependent samples was calculated between classifiers from gene expression, chromosomal and clinico-pathological data and yielded a significant ranking. prediction of metastatic spread. Gene expression data analyzed with diagonal linear discriminant analysis grouped patients according to their risk, misclassifying tumors from only two of 28 patients. Unsupervised learning (cluster analysis) revealed a correct grouping in 24 of 27 patients. Two samples (108-97 and 193-97) were misclassified in both analyses. Sample 210-97, which was a non-metastatic tumor with monosomy 3 was grouped into a separate third cluster, indicating a unique gene expression pattern. Interestingly, sample 210-97 was appropriately categorized as part of the cluster without subsequent metastases, when the 42 genes identified to discriminate high-from low-risk tumors for subsequent metastases were used to perform cluster analysis, suggesting that the pre-selected 42 classifying genes play a curial role in metastatic spread. CGH-based discriminant analysis of the same type grouped patients according to their risk for metastases with a significantly lower precision. Thus, in our hands gene expression profiling appeared to be the most suitable method for stratification of patients with high-risk uveal melanomas in prospective clinical trials, as has been suggested for a variety of hematopoietic 17, 18 as well as solid [19] [20] [21] tumors. Two other groups have investigated gene expression in uveal melanomas. The first report by Tschentscher et al 13 defined the gene expression profile of tumors carrying monosomy 3 by presenting 201 significantly differentially expressed genes. Onken et al 14 described the prognostic value of gene expression analysis similar to our study identifying 62 significantly differentially expressed genes. Surprisingly, only one gene (phosphoinositide-3-kinase, regulatory subunit 4, p150) could be identified as differentially expressed in all three studies. However, all three gene lists were able to group our patient cohort better than all other risk factors for subsequent metastases.
Even if all three studies were of limited sample size, a significant grouping into only two clinical courses was possible in all studies reflecting the biological difference in metastasizing vs non-metastasizing tumors. None of the studies found a third group by unsupervised hierarchical clustering indicating the homogeneity of the tumor biology. The consistently identified two-groupscluster allowed a statistically significant comparison even with a small sample size. Additionally, the population genetic differences between all three studies may contribute to the small overlap of differentially expressed genes. However, more critical appears to be the methodological variations of feature selection and different Affymetrix GeneChips. This exemplarily could be shown by using the same or different Affymetrix GeneChips in different laboratories to subgroup AML samples. 18 Consistently samples were correctly grouped regardless of the used GeneChip or the laboratory. But importantly, lists of differentially expressed genes were substantially different indicating the issue of cutoff points for significantly differentially expressed genes. Defining classifying genes based on rank list appears problematic although associated with loss of information by setting a cutoff point to include and exclude probe sets. Furthermore, biological processes might be redundantly regulated by the expression of many different genes in different pathways. Accordingly, in our ocular melanoma study, the set of selected genes from our sample set worked, and the presented gene lists from Tschentscher and Onken also worked well on our sample metastases n n n n n n n n n n n n y n n y y y y y y y y y y n y n ACADVL  TSC22D1  S100A13  SGCB  ARMC9  DERL1  ARMC9  ANXA4  ANXA4  ACTR3  PTP4A3  CUGBP2  ME1  TRAM1  SLC1A4  SLC1A4  SLC1A4  C4A  PTPLA  PTPLA  SPON2   RPL14  CMTM6  LMCD1   FDPT1  FDPT1  TFAP2A  SH3BP4  SMARCC1  MBNL1  RAF1  MKRN2  ARIH2  YEATS2  TATDN2  CRTC3  USP4  GTBBP8  HERC1  TJP2  TSPAN6  PIK3R4  GCA  LOC653754  AZGP1  MTUS1  DLC1  ROPN1B M005 Figure 4 Gene expression profiling: Hierarchical cluster analysis based on 50 classifying probe sets determined by discriminant analysis (up (red) and down (green) regulated genes in metastasizing primary uveal melanoma). The choice of the 50 probe sets was not crossvalidated.
set. However, because of the redundancy of regulation and different cutoff points to include and exclude genes from further analysis, list of selected genes within the sample sets do not overlap considerably. All three studies showed, that the presence of monosomy 3 significantly influenced the expression profile of uveal melanoma. However, the complete data for all our patients demonstrated the ability of gene expression data to predict a high risk of metastases even in patients without the strong risk factor monosomy 3.
Taken together, gene expression profiling of our patient cohort provides a highly predictive pattern for the risk of metastases. Our observation suggests, that gene expression profiling can be used for stratification of patients in prospective clinical trials. Despite the considerable variability observed in three studies, however, different discriminating gene lists group patients more precisely according to their risk for subsequent metastases than chromosomal or clinicopathological data. Further, the identification of two genes linked to chromosomal alterations that are consistently predictive for metastases over 3 different analyses is of interest for detailed elucidation of the molecular basis of the metastatic process and for designing targeted treatment strategies.
